Molecular Approaches in Fetal Malformations, Dynamic Anomalies and Soft Markers: Diagnostic Rates and Challenges-Systematic Review of the Literature and Meta-Analysis
- PMID: 35328129
- PMCID: PMC8947110
- DOI: 10.3390/diagnostics12030575
Molecular Approaches in Fetal Malformations, Dynamic Anomalies and Soft Markers: Diagnostic Rates and Challenges-Systematic Review of the Literature and Meta-Analysis
Abstract
Fetal malformations occur in 2-3% of pregnancies. They require invasive procedures for cytogenetics and molecular testing. "Structural anomalies" include non-transient anatomic alterations. "Soft markers" are often transient minor ultrasound findings. Anomalies not fitting these definitions are categorized as "dynamic". This meta-analysis aims to evaluate the diagnostic yield and the rates of variants of uncertain significance (VUSs) in fetuses undergoing molecular testing (chromosomal microarray (CMA), exome sequencing (ES), genome sequencing (WGS)) due to ultrasound findings. The CMA diagnostic yield was 2.15% in single soft markers (vs. 0.79% baseline risk), 3.44% in multiple soft markers, 3.66% in single structural anomalies and 8.57% in multiple structural anomalies. Rates for specific subcategories vary significantly. ES showed a diagnostic rate of 19.47%, reaching 27.47% in multiple structural anomalies. WGS data did not allow meta-analysis. In fetal structural anomalies, CMA is a first-tier test, but should be integrated with karyotype and parental segregations. In this class of fetuses, ES presents a very high incremental yield, with a significant VUSs burden, so we encourage its use in selected cases. Soft markers present heterogeneous CMA results from each other, some of them with risks comparable to structural anomalies, and would benefit from molecular analysis. The diagnostic rate of multiple soft markers poses a solid indication to CMA.
Keywords: chromosomal microarray; exome sequencing; fetal malformations; genetic counseling; genome sequencing; molecular approaches; prenatal diagnosis; soft markers; structural anomalies.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies.Ultrasound Obstet Gynecol. 2022 Jul;60(1):59-67. doi: 10.1002/uog.24885. Ultrasound Obstet Gynecol. 2022. PMID: 35229910 Free PMC article.
-
Prenatal exome sequencing and chromosomal microarray analysis in fetal structural anomalies in a highly consanguineous population reveals a propensity of ciliopathy genes causing multisystem phenotypes.Hum Genet. 2022 Jan;141(1):101-126. doi: 10.1007/s00439-021-02406-9. Epub 2021 Dec 1. Hum Genet. 2022. PMID: 34853893
-
Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis.Prenat Diagn. 2022 May;42(6):662-685. doi: 10.1002/pd.6115. Epub 2022 May 7. Prenat Diagn. 2022. PMID: 35170059 Free PMC article.
-
Whole Genome Sequencing in the Evaluation of Fetal Structural Anomalies: A Parallel Test with Chromosomal Microarray Plus Whole Exome Sequencing.Genes (Basel). 2021 Mar 6;12(3):376. doi: 10.3390/genes12030376. Genes (Basel). 2021. PMID: 33800913 Free PMC article.
-
Chromosomal Microarray Analysis in Fetuses Detected with Isolated Cardiovascular Malformation: A Multicenter Study, Systematic Review of the Literature and Meta-Analysis.Diagnostics (Basel). 2022 May 27;12(6):1328. doi: 10.3390/diagnostics12061328. Diagnostics (Basel). 2022. PMID: 35741137 Free PMC article. Review.
Cited by
-
Application of Whole-Exome Sequencing in the Prenatal Diagnosis of Foetuses With Central Nervous System Abnormalities.Mol Genet Genomic Med. 2024 Oct;12(10):e70016. doi: 10.1002/mgg3.70016. Mol Genet Genomic Med. 2024. PMID: 39359128 Free PMC article.
-
Identification of novel biallelic mutations in CFAP53 associated with fetal situs inversus totalis and literature review.J Appl Genet. 2025 Feb 19. doi: 10.1007/s13353-025-00950-y. Online ahead of print. J Appl Genet. 2025. PMID: 39969775
-
Global, regional, and national burden of congenital musculoskeletal and limb anomalies, 1990-2021: a systematic analysis of the global burden of disease in 2021.Trop Med Health. 2025 May 12;53(1):68. doi: 10.1186/s41182-025-00750-4. Trop Med Health. 2025. PMID: 40355938 Free PMC article.
-
Chromosomal abnormalities detected by chromosomal microarray analysis and pregnancy outcomes of 4211 fetuses with high-risk prenatal indications.Sci Rep. 2024 Jul 10;14(1):15920. doi: 10.1038/s41598-024-67123-5. Sci Rep. 2024. PMID: 38987582 Free PMC article.
-
Clinical utility of trio whole exome sequencing in fetuses with ultrasound anomalies.Hum Genomics. 2025 Apr 5;19(1):37. doi: 10.1186/s40246-025-00745-6. Hum Genomics. 2025. PMID: 40188065 Free PMC article.
References
-
- Crane J.P., LeFevre M.L., Winborn R.C., Evans J.K., Ewigman B.G., Bain R.P., Frigoletto F.D., McNellis D. A randomized trial of prenatal ultrasonographic screening: Impact on the detection, management, and outcome of anomalous fetuses. ACOG Curr. J. Rev. 1995;8:15–16. doi: 10.1016/S0002-9378(94)70040-0. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources